To date, the targeting of two MM surface antigens, CD-38 and SLAMF7, has led to the Food and Drug Administration (FDA) approval of moAbs Daratumumab or Isatuximab and Elotuzumab, respectively, for MM treatment. Here, CD38 is linked to Miyoshi myopathy.